NovoCure
NVCR
264 hedge funds and large institutions have $4.1B invested in NovoCure in 2020 Q2 according to their latest regulatory filings, with 48 funds opening new positions, 95 increasing their positions, 80 reducing their positions, and 54 closing their positions.
19% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 80
1.91% less ownership
Funds ownership: 70.77% → 68.86% (-1.9%)
3% less funds holding
Funds holding: 271 → 264 (-7)
11% less first-time investments, than exits
New positions opened: 48 | Existing positions closed: 54
14% less capital invested
Capital invested by funds: $4.75B → $4.1B (-$647M)
28% less call options, than puts
Call options by funds: $49.9M | Put options by funds: $69.7M
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$61.3M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$60.1M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$53.1M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$40M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$24.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$92.1M |
| 2 |
BlackRock
New York
|
-$90.2M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$51M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$43.6M |
| 5 |
State Street
Boston,
Massachusetts
|
-$43.1M |
NVCR Hedge Fund Activity: Q2 2020 in Review
264 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q2 2020, worth a combined $4.1B — down 14% from $4.75B a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of NVCR and 48 opened new positions — a net loss of 6 holders — while 80 trimmed existing stakes and 95 added.
The largest buyer was Capital International Investors, adding an estimated $61.3M. The largest seller was Fidelity Investments, cutting an estimated $92.1M.
- 264 institutional investors held NovoCure (NVCR) as of Q2 2020, down from 271 in Q1 2020.
- Funds reported $4.1B of NovoCure stock for Q2 2020, down 14% quarter-over-quarter.
- 48 funds opened new NovoCure positions in Q2 2020 and 54 closed out, a net change of -6 holders.
- The largest NovoCure buyer in Q2 2020 was Capital International Investors, an estimated $61.3M added.
- The largest NovoCure seller in Q2 2020 was Fidelity Investments, an estimated $92.1M sold.
Based on aggregated 13F filings for Q2 2020.